Author: Eagle Biosciences

image by the Guardian

A ground breaking gene therapy has the potential to help
mend damaged nerves in the spin and help those paralyzed by spinal cord
injuries. This new therapy works by utilizing an enzyme called chondroitinase.
This enzyme has the ability to break down scar tissue and by doing so allows
severed nerves to connect again.

Rats treated with this therapy for a period of time were
able to relearn some basic skill such as grabbing with their limbs. The therapy
can treat large areas of the spinal cord at once, and the hope is that one day
the treatment will be able to help people with spinal cord injuries regain the
ability to perform some daily tasks such as using utensils, picking up things,
and writing.

Though this therapy is a breakthrough in regenerative
medicine there is still some hurdles that need to be cleared before it can be
brought to human trials. The research team needs to prove the treatment can
work effectively in larger mammals before bringing it to human trials. They
also want to find a way to stop the therapy for working once the spine is
healed.  

Read More.

References:

1. Sample Ian. “Paws and play: gene treatment helps rats with
spinal cord injuries regain their nerve.” The Guardian. 14 Jun 2018.  

The Eagle Biosciences DM-1 Antibody Drug Conjugate ELISA Assay Kit was recently used in a study researching targeted cancer therapies. This kit is a part of our line of Cancer Biomarker Kits. These cancer biomarker kits are highly sensitive and specific assays tests for quantifying of specific biomarkers in various sample types for university, pharmaceutical, or clinical research.

Levels of DM-1 conjugate (Trastuzumab emtansine) were determined usign Eagle Biosciences DM-1 Antibody Drug Conjugate ELISA Assay Kit.

Read More.

Reference:

[1]. Verkade, J.M.M.; WiJdeven, M.A.; van Geel, R.; Janssen, B.M.G.; van Berkel, S.S.; van Delft, F.L. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates. Antibodies 2018 7:12.

Mediagnost along with Eagle Biosciences, Inc. has released an improved test for human Adiponectin in serum and plasma samples*. This Total Adiponectin ELISA Assay Kit has been upgraded with the following features;

• is extremely sensitive (less than 0.3 ng/ml)
• is fast: incubation time a total of 1 hour and 45 minutes
• Single Standards with 2, 10, 30, 70, 100 ng/ml human Adiponectin are provided in the Kit
• 2 Control Sera are provided for quality control purposes according GLP
• is calibrated with native Adiponectin
• uses high affinity monoclonal antibodies against human Adiponectin
• Microtiter plates are separately breakapart
• Available for human, mouse and rat samples

For more information click here

Read IFU Here 

*The Adiponectin ELISA is for Research Use Only

We have been very busy these past few months gathering a bunch of new products to offer our great and loyal customers! Some of these new products have been added to our ever-growing Bone Metabolism Assays.

Research on the effects of various cancers and abnormalities in the skeletal system are on the rise and we are excited to start offering more tests! 

Soluble Semaphorin 4D ELISA: 

For the direct determination of soluble Semaphorin 4D in human plasma samples. 

Semaphorin 4D (SEMA4D or CD100) is a member of a family of trans membranes and secreted proteins that regulates key cellular functions and is involved in cell-cell communication. SEMA4D participates in numerous physiological processes such as axon guidance, immune regulation, angiogenesis, tumor progression, and bone metabolism. SEMA4D has emerged to a novel therapeutic target in cancer and in bone diseases. 

Bioactive Sclerostin ELISA:

For the quantitative determination of bioactive sclerostin in human serum, EDTA plasma, and citrate plasma.

Sclerostin is nearly exclusively produced in osteocytes. Mutations in the Sclerostin (SOST) gene can cause sclerosteosis and van Buchem disease which are bone dysplasia disorders characterized by progressive skeletal overgrowth. Sclerostin levels are altered in response to hormonal stimuli or due to pathophysiological conditions. Sclerostin concentrations are increased in disorders such as hypoparathyroidism, Paget’s disease, multiple myeloma and in cancer induced bone diseases.

OsteomiR (Coming Soon!) 

For the quantification of selected microRNA biomarker candidates for fracture-risk in postmenopausal and diabetic osteoporosis in human serum samples.

MicroRNAs are small non-coding RNAs that regulate gene expression through RNA interference and therefore contribute to the regulation of correct cell and tissue function. MicroRNA secretion (contained in exosomes or microvesicles) has been observed in many different cell types, and is believed to serve as an endocrine pathway for cell-to-cell communication. Therefore, the analysis of circulating microRNAs in serum, urine or saliva can be used to obtain valuable information about tissue physiology and pathophysiology. Circulating microRNAs are a novel class of relevant serum biomarkers.

Keep an eye out for all the other great new products we are releasing in the next few months!

Looking for a specific ELISA? Email us what you’re looking for and we can try to make it happen!

Eagle Biosciences Vitamin D ELISA Kit has been used once again in breakthrough research! 

Background: Influenza continues to cause significant morbidity and mortality each year. Vaccination is the primary prevention; however, its effectiveness may be limited even among young, healthy adults. Vitamin D deficiency is highly prevalent and may be associated with poor vaccine immunogenicity and an increased risk for respiratory infections.

Methods: We conducted a retrospective cross-sectional study among young, healthy military personnel to evaluate the associations between 25(OH)D levels with post-influenza vaccination antibody titers (seroprotection defined as a titer of ≥1:40 post-vaccination) and healthcare encounters for respiratory infections during the 2009-2010 influenza season. 25(OH)D levels were analyzed as continuous and categorical [normal (>30 ng/ml), insufficient (20-30 ng/ml), and deficient (<20 ng/ml)] variables. Separate univariate and multivariable logistic regression models were utilized to determine the associations between 25(OH)D levels with antibody responses and respiratory conditions adjusting for possible confounders.

Results: A total of 437 subjects were evaluated. Most participants were young adults (91% were 18-39 years of age), 50% were male, and 56% resided in the southern U.S. Overall, 152 (35%) were vitamin D deficient, 167 (38%) insufficient, and 118 (27%) had normal 25(OH)D levels. There were no demographic differences by 25(OH)3 category. Only 224 (51%) demonstrated a seroprotective anti-influenza post-vaccination titer, which did not vary by categorical 25(OH)D levels [vitamin D deficient vs. normal: OR 1.10 (0.68-1.78) and insufficient vs. normal: OR 1.25 (0.78-2.01)] or continuous vitamin D levels [OR 0.98 (0.84-1.15)]. There were no associations with respiratory diagnoses between the vitamin D groups.

Conclusion: Vitamin D insufficiency and deficiency were highly prevalent despite evaluating a young, healthy adult population. There were no significant associations between 25(OH)D levels and post-vaccination antibody titers or respiratory infections. Strategies for improving influenza vaccine responses are needed since only one-half of vaccinees demonstrated seroprotective anti-influenza titers.

Reference: Rachel Lee, MD¹, Seunghyun Won, PhD^2,3, Christian Hansen, BS¹ and Nancy Crum-Cianflone, MD, MPH^2,4,5, (1)Operational Infectious Diseases, Naval Health Res. Ctr., San Diego, CA, (2)Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, (3)Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, (4)Scripps Mercy Hospital, San Diego, CA, (5)Naval Medical Center San Diego, San Diego, CA